Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 16/20 | 0.68 |
| ▸ | CACNA1G | O43497 | 7/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 8/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 8/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18761567 | 0.84 | CACNA1H (0.52) | CACNA1HCACNA1GCACNA1BCACNA1C | |
| SCHEMBL15844552 | 0.81 | CACNA1H (1.00) | CACNA1HCACNA1GCACNA1BCACNA1C | |
| SCHEMBL17437505 | 0.80 | CACNA1H (0.42) | CACNA1HEGLN1 | |
| Hydrochloric Acid SCHEMBL12495897 | 0.80 | CACNA1H (0.98) | CACNA1HCACNA1GCACNA1BCACNA1C | |
| SCHEMBL17437401 | 0.79 | CACNA1H (0.80) | CACNA1HCACNA1GCACNA1BCACNA1C | |
| SCHEMBL17437524 | 0.77 | CACNA1H (0.48) | CACNA1HCACNA1GCACNA1BCACNA1C | |
| SCHEMBL17437508 | 0.73 | CACNA1H (0.51) | CACNA1HCACNA1GCACNA1BCACNA1C | |
| SCHEMBL10284440 | 0.72 | CACNA1H (0.63) | CACNA1HCACNA1GCACNA1BCACNA1CEGLN1 | |
| SCHEMBL17342643 | 0.72 | CACNA1H (0.78) | CACNA1HCACNA1GCACNA1BCACNA1C | |
| SCHEMBL20623233 | 0.70 | CACNA1H (0.62) | CACNA1HCACNA1GCACNA1BCACNA1CEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208023-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | EPIRUS BIOPHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20160016939-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | NATIONAL CENTER FOR ADDICTION STUDIES AND TREATMENT FOUNDATION | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208023-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPV1, SCN1A | CACNA1H 32/4885CACNA1G 13/4885CACNA1B 9/4885 |
| US-20160016939-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, TRPV1, SCN1A | CACNA1H 32/4885CACNA1G 13/4885CACNA1B 9/4885 |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, SCN1A, CACNA1S | CACNA1H 20/4885CACNA1G 7/4885CACNA1B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.